#
Title
1

Weekly Insulin Icodec Now Available for Type 2 Diabetes

2

Tech, Screening, and Care Highlights from ADCES 2026

3

Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss

4

Evolving Wearable Insulin Delivery Devices - AID, CGM, and More

5

Tegoprubart and Freedom from Insulin in Type 1 Diabetes

6

Signos and the Science of Weight Loss

7

Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients

8

CONNECT, TRANSCEND, and TRIUMPH at ADA 2026

9

The International Diabetes Federation and Care Access in India, With Amit Gupta, MBBS, DNB

10

Diabetes Technology and Treatment in the UK, With Ketan Dhatariya, MD, PhD, MS

11

Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS

12

The ADA’s Statement on Diabetes Tech Integration, With Eugene Wright Jr., MD

13

FDA Approves Afrezza Inhaled Insulin for Pediatric Patients

14

CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA

15

ADA Scientific Sessions 2026 Preview

16

Updates for T1D Treatment in Pregnancy and Pediatrics

17

Nutrition, Medication, and Treatment in Obesity With Elizabeth Bauer, MD

18

The Push for Early-Stage T1D Screening and Treatment, With Linda DiMeglio, MD, MPH

19

Orforglipron Availability, Amazon Pharmacy, and Dosing Considerations

20

The G7 15-Day System and CGM Innovations at Dexcom, With Jessica Castle, MD

21

FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D

22

2026 AACE Guidelines for Type 2 Diabetes

23

Orforglipron Receives FDA Approval for Chronic Weight Management

24

Q1 2026 Updates from Tandem Diabetes Care, with Laurel Messer, PhD, RN

25

ATTD 2026 Recap

26

Orforglipron, Retatrutide, and Other GLP-1 Updates

27

Launch of the Zepbound KwikPen

28

Implantable Insulin Pumps and Interoperability

29

Oral Ozempic and the Risks of Compounding Formulas

30

Tech Updates on Twiist, MiniMed Go, and More

31

Reviewing the New US Dietary Guidelines with Susan Weiner, MS

32

Therapeutic Updates from the ADA 2026 Standards of Care

33

Orforglipron, Cagrilintide, and the Libre Assist

34

2026 Technology Updates and American Diabetes Association Standards of Care

35

Reacting to Retatrutide and TRIUMPH-4 Topline Data

36

Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D

37

Updates on Dexcom G7 and Semaglutide Pricing

38

Oral Semaglutide and SELECT at DTM 2025

39

Biolinq Shine, Insulin Icodec, and Eli Lilly's Pipeline

40

Celebrating 150 Episodes!

41

What's New at Medtronic Diabetes With Bob Vigersky, MD

42

Results of ATTAIN-1 and STEP UP Phase 3 Trials

43

Milestones for MiniMed 780G and Signos CGM for Weight Loss

44

Semaglutide & Tirzepatide Updates at ESC Congress 2025

45

FDA Approves Semaglutide (Wegovy) for MASH

46

ADCES 2025 Part 3 & Diabetes Tech Updates

47

ADCES 2025 Recap Part 2

48

Orforglipron Topline Results & ADCES 2025 Part 1

49

Tirzepatide and SURPASS-CVOT Topline Results

50

Guideline Updates for Diabetes & Pregnancy

51

GLP-1s, SGLT2s, and Diabetes Barbie at ENDO 2025

52

Upcoming Research on Type 1 Diabetes in Pregnancy with Carol Levy, MD

53

BELIEVE, GLP-1/GIP Agonists, and CATALYST Results at ADA 2025

54

American Diabetes Association 2025 Trial Recap - Part 1

55

The Diabetes Collective, with Rachael Sood, RN, MSN, APRN

56

Addressing America's Shortage of Diabetes Care Providers, with Jay Shubrook, DO, & Conan Tu, MD

57

CATALYST Trial, Mifepristone, and Hypercortisolism in T2D, with John Buse, MD, PhD

58

Updates from Dexcom at ADA 2025, with Kevin Sayer

59

REDEFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD

60

ADA 2025 Preview

61

American Diabetes Association Consensus Report on MASLD

62

May 2025 Diabetes Tech & Breakthrough T1D Updates

63

INHALE-3 Trial and Afrezza, With Roy Beck, MD, PhD

64

Diabetes Dialogue: AACE 2025 Recap

65

Real-World Impact of iLet Bionic Pancreas, With Steven Russell, MD, PhD

66

Luna Automated Insulin Delivery, With Jon Brilliant and John Sjölund

67

Tirzepatide vs Semaglutide for Obesity, Understanding SURMOUNT-5

68

Diabetes Dialogue: Dexcom G7, Libre App, and Medtronic Simplera Sync

69

Diabetes Dialogue: Semaglutide for MASH in ESSENCE Trial, With Arun Sanyal, MD

70

Diabetes Dialogue: CATALYST Reveals High Prevalence of Hypercortisolism in T2D

71

Diabetes Dialogue: Oral GLP-1 Orforglipron in ACHIEVE-1 Trial

72

SCORE, Semaglutide, and ACC Wrap-up

73

Diabetes Dialogue: Screening for Presymptomatic T1D with Rifka Schulman-Rosenbaum, MD

74

Diabetes Dialogue: SOUL and STRIDE Trials from ACC 2025

75

Diabetes Dialogue: Updates and News from ATTD 2025 Part 1

76

Bionic Pancreas Brings AID to Primary Care & Telehealth

77

Diabetes Dialogue: Understanding Control-IQ+ AID Algorithm with Laurel Messer, PhD, RN

78

Impact of NovoCare Pharmacy, LillyDirect Self Pay on GLP-1 RA Access

79

1: News and Updates in Diabetes Care from February 2025

80

Omnipod 5 and Medtronic 780G for Type 2 Diabetes

81

Understanding Semaglutide (Ozempic) in CKD and T2D

82

ADA’s 2025 Standards of Care in Diabetes Therapeutics

83

ADA’s 2025 Standards of Care in Diabetes Technology

84

The Evolving Role of Registered Dietitian Nutritionists in Obesity

85

Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas

86

Insights on INHALE-1 and CATALYST Trials

87

Exploring New Horizons in Incretin Therapy for Diabetes and Weight Loss

88

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

89

Celebrating 25 Years of CGM, with Irl Hirsch, MD

90

News and Updates in Diabetes at AHA 2024

91

Tirzepatide’s Long-Term Obesity Data

92

Latest Updates on Semaglutide

93

Diabetes Tech Updates in October 2024

94

What to Know About the Eversense 365 CGM, with Brian Hansen

95

Lingo Availability & Embecta's Tubeless Patch Pump

96

Real-World Experience with Dexcom Stelo

97

Sotagliflozin for T1D and Other ADCES Highlights

98

First 10 Prices Announced from CMS Price Negotiations

99

Navigating ADCES 2024

100

SUMMIT and FINEARTS-HF, with Muthiah Vaduganathan, MD, MPH

101

Simplera CGM and Medtronic's Partnership with Abbott

102

CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD

103

New Early-Stage T1D Monitoring Guidance, with Anastasia Albanese-O'Neill, PhD, APRN

104

INHALE-3 and Diabetes Tech Updates, with Grazia Aleppo, MD

105

Blue Circle Health, with Monica Gomberg, MD

106

Advances in AID and CGM at ADA 2024, with Davida Kruger, NP

107

ADA Introduces Obesity Association, with Robert Gabbay, MD, PhD

108

Patient Considerations for Inhaled Insulin, with Carol Levy, MD

109

ADA 2024 Diabetes Technology Recap

110

June 2024 Updates in Diabetes Technology and T1D

111

GLAM and CRISTAL, Updates in Pregnancy

112

FLOW Trial and Semaglutide's Benefit in Chronic Kidney Disease

113

2024 ACP Type 2 Diabetes Recommendations

114

STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

115

What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD

116

Hot Topics and Updates from ATTD 2024

117

T1D Glycemic Improvement and CRISTAL at ATTD 2024

118

FLOW Trial and Chronic Kidney Disease Updates, with Brendon Neuen, MBBS, PhD

119

Dexcom Stelo and CGM Updates, with Jake Leach

120

Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD

121

SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD

122

Understanding MARD, Comparing Popular CGM Sensors

123

ATTD 2024 Preview

124

Time in Range, CGM Metrics for Predicting Outcomes in Diabetes

125

Tirzepatide in Type 1 Diabetes, with Viral Shah, MD

126

Diabetes Technology Updates in January 2024

127

Updates in Management of Hypercortisolism in Type 2 Diabetes, with Ralph DeFronzo, MD

128

Latest Updates on Diabetes Management in Pregnancy

129

Baricitinib & the Potential Disease-Modifying Therapies in Type 1 Diabetes

130

Diabetes Dialogue: 2023 Top Episodes Recap

131

Key Updates in ADA Standards of Care—2024

132

Diabetes Technology Updates and Standards of Care—2024

133

SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023

134

Tirzepatide (Zepbound) Approved for Chronic Weight Management

135

Diabetes Dialogue: Automated Insulin Delivery News in October 2023

136

SURMOUNT-3 and SURMOUNT-4 Data

137

PROTECT Data and Teplizumab in Newly Diagnosed T1D

138

Accu-Chek Solo and Abbott Acquiring Bigfoot Biomedical

139

Making Sense of Semaglutide in Type 1 Diabetes

140

Clearance of Tandem Mobi and Welldoc's BlueStar Platform

141

Addressing Health Disparities with Diabetes Technology, with Etty Vider, PharmD

142

What Medicare Drug Price Negotiations Mean for Diabetes

143

Diabetes Dialogue: The Role of Nutrition in Diabetes Management, with Dawn Noe, RDN, LD

144

Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs

145

Diabetes Dialogue: ADCES 2023 Recap

146

Diabetes Dialogue: ADA 2023 Recap

147

Diabetes Dialogue: Latest News in Insulin Delivery, with Gary Scheiner, MS

148

Diabetes Dialogue: Embracing Diabetes Tech and Social Media as a Clinician, with David Ahn, MD

149

Diabetes Dialogue: Establishing Time in Range as a Primary Glucose Metric

150

Diabetes Dialogue: TRANSITION-T2D, with Paloma Rodriguez, MD, and Kevin Pantalone, DO

151

Diabetes Dialogue: "Second-Generation" Obesity Medications, with W. Timothy Garvey, MD

152

Diabetes Dialogue: Improving Implementation of New Technology, with Cari Berget, RN, MPH

153

Diabetes Dialogue: Managing & Addressing Mental Health Needs in Diabetes

154

Diabetes Dialogue: Reforming Language in Metabolic Disease, with Jane Dickinson, RN, PhD

155

Diabetes Dialogue: Diabetic Foot Ulcers and Social Determinants of Health

156

Diabetes Dialogue: What to Know about the iLet Bionic Pancreas

157

Diabetes Dialogue: Breaking Down AACE's New Type 2 Diabetes Management Algorithms

158

Diabetes Dialogue: Breaking Down the Medtronic 780G Approval, with Robert Vigersky, MD

159

Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D

160

Diabetes Dialogue: CMS Expansion Ushers in New Age of CGM Access

161

Diabetes Dialogue: ATTD 2023 Recap

162

Diabetes Dialogue: Practical Updates in Pediatric Diabetes, with Stuart Weinzimer, MD

163

Diabetes Dialogue: Technology Guidelines and Uptake in Diabetes, with Grazia Aleppo, MD

164

Diabetes Dialogue: The Role of Patient Voice in Diabetes Management

165

Diabetes Dialogue: Actualizing the Optimal Role of Inhaled Insulin, with Joanne Rinker, MS, RDN

166

Diabetes Dialogue: Updates in Diabetes Management from ATTD 23, with Irl Hirsch, MD

167

Diabetes Dialogue: Screenings for Hearing Loss in Diabetes, with Joanne Rinker, MS, RDN

168

Diabetes Dialogue: Mental Health and PRO Standardization, with Katharine Barnard-Kelly, PhD

169

Diabetes Dialogue: FDA Clearance of Tidepool Loop

170

Diabetes Dialogue: ADCES DTC 22, with Jennifer Okemah, RD, and Gary Scheiner, MS

171

Diabetes Dialogue: The Prospect of a Bionic Pancreas, with Steven Russell, MD, PhD

172

Diabetes Dialogue: December 2022

173

Diabetes Dialogue: The Psychology of Diabetes Management, with Jill Weissberg-Benchell, PhD

174

Diabetes Dialogue: Updates in Inpatient Management of Diabetes, with Jane Jeffrie Seley, DNP, MPH

175

Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes

176

Diabetes Dialogue: Obesity Updates, with Lydia Alexander, MD

177

Diabetes Dialogue: GLP-1 RA Shortage & ADA/KDIGO Recommendations

178

Diabetes Dialogue: EASD 2022 and Recent CGM News

179

Diabetes Dialogue: September 2022

180

Diabetes Dialogue: ADCES 2022 Recap

181

Diabetes Dialogue: Updates in Diabetes Management at ADCES, with Jennifer Clements, PharmD

182

Diabetes Dialogue: Sit Down with Diabetes Care and Education Specialist of the Year, Anastasia Albanese-O'Neill, PhD

183

Diabetes Dialogue: T1D Exchange, with David Walton

184

Diabetes Dialogue: Exploring DiabetesWise, with Korey Hood, PhD

185

Diabetes Dialogue: The Race to Cure T1D

186

Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, & Misdiagnosis of T1D

187

Diabetes Dialogue: Inside ADA 2022

188

Diabetes Dialogue: Inequities & Barriers in Diabetes, with Jasmine Gonzalvo, PharmD

189

Diabetes Dialogue: Frontline Perspective from ADA 2022, with Gary Scheiner, MS, CDE

190

Diabetes Dialogue: Optimizing CGM Uptake in Primary Care

191

Diabetes Dialogue: Tirzepatide in Action & AACE 2022 Recap

192

Diabetes Dialogue: ATTD 2022 Recap

193

Diabetes Dialogue: April 2022

194

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

195

Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

196

Subcutaneous Semaglutide for Weight Loss with Thomas Wadden, PhD

197

Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD

198

Dietary Interventions and the Role of Nutrition in Obesity with Ariana Chao, PhD, CRNP

199

Jeffrey Curtis, MD: Osteoporosis in 2020

200

Osilodrostat and Treatment of Cushing's Disease

201

Terri Lipman, PhD, CRNP: Addressing Racial Disparities in Medicine

202

Raymond Douglas, MD, PhD: State of Thyroid Eye Disease in 2020

203

Muthiah Vaduganathan, MD: Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1 RAs

204

Prof. Hiddo Heerspink: Insights from DAPA-CKD

205

Joshua Denson, MD: Metabolic Syndrome and COVID-19 Outcomes

206

Robert Busch, MD: Topline Results of EMPEROR-REDUCED

207

Diabetes Research & COVID-19